Precigen/$PGEN
1D1W1MYTD1Y5YMAX
Capital at risk
About Precigen
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
- Ticker
- $PGEN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 160
- Headquarters
- Germantown, United States
- Website
- precigen.com
Precigen Metrics
BasicAdvanced
$2.5B
-
-$0.98
1.01
-
Price and volume
Market cap
$2.5B
Beta
1.01
52-week high
$7.72
52-week low
$2.99
Average daily volume
5.3M
Financial strength
Current ratio
4.578
Quick ratio
3.756
Long term debt to equity
223.265
Total debt to equity
225.686
Interest coverage (TTM)
-4.06%
Profitability
EBITDA (TTM)
-35.359
Gross margin (TTM)
53.01%
Net profit margin (TTM)
-183.98%
Operating margin (TTM)
-46.08%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
-18.14%
Return on equity (TTM)
-837.08%
Valuation
Price to revenue (TTM)
27.426
Price to book
56.28
Price to tangible book (TTM)
95.06
Price to free cash flow (TTM)
-20.403
Free cash flow yield (TTM)
-4.90%
Free cash flow per share (TTM)
-0.336
Growth
Revenue change (TTM)
1,875.05%
Earnings per share change (TTM)
129.04%
3-year revenue growth (CAGR)
57.11%
10-year revenue growth (CAGR)
-7.69%
3-year earnings per share growth (CAGR)
113.93%
10-year earnings per share growth (CAGR)
-4.69%
What the Analysts think about Precigen
Analyst ratings (Buy, Hold, Sell) for Precigen stock.
Analyst projections of the future price of Precigen stock.
Bulls say / Bears say
Achieved quarterly net profitability in Q2 2026 with GAAP net income of $20.07 million on total revenues of $54.98 million, driven by PAPZIMEOS net sales of $53.1 million. (Morningstar)
PAPZIMEOS demonstrated durable clinical efficacy in RRP, with 83 percent of complete responders remaining surgery-free after three years and 95 percent reduction in surgeries by year 3, with no new safety concerns reported. (Reuters via TradingView)
Shares of PGEN have rallied over 71 percent year-to-date, trading at a 52-week high amid growing commercial and pipeline optimism. (Bloomberg)
PAPZIMEOS accounted for approximately 97 percent of Q2 2026 revenue, creating concentration risk from reliance on a single product. (Morningstar)
Key pipeline assets PRGN-3005, PRGN-3006, and PRGN-3007 remain in early clinical stages under the UltraCAR-T platform, subject to typical high trial and regulatory attrition risks. (SEC Filings)
Cash, cash equivalents, and investments of $38.7 million as of June 30, 2026 may be insufficient to sustain both ongoing commercialization and pipeline development without additional financing. (PR Newswire)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
Precigen Financial Performance
Revenues and expenses
Precigen Earnings Performance
Company profitability
Upcoming events
No upcoming events
Precigen News
AllArticlesVideos
Funds containing Precigen
AllUSDGBPEUR
Fund name | Fund size | $PGEN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.14% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.14% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.